DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The "Hemochromatosis - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Hemochromatosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hemochromatosis (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hemochromatosis (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemochromatosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Companies Mentioned

Ionis Pharmaceuticals Inc La Jolla Pharmaceutical Company Protagonist Therapeutics Inc Silence Therapeutics Plc Vifor Pharma AG

Key Topics Covered

Introduction Report Coverage Hemochromatosis - Overview Hemochromatosis - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Hemochromatosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hemochromatosis - Companies Involved in Therapeutics Development Ionis Pharmaceuticals Inc La Jolla Pharmaceutical Company Protagonist Therapeutics Inc Silence Therapeutics Plc Vifor Pharma AG Hemochromatosis - Drug Profiles BBI-001 - Drug Profile Product Description Mechanism Of Action R&D Progress Fusion Protein to Replace Hepcidin for Iron Overload Disorders - Drug Profile Product Description Mechanism Of Action R&D Progress IONISTMPRSS-6LRx - Drug Profile Product Description Mechanism Of Action R&D Progress LJPC-401 - Drug Profile Product Description Mechanism Of Action R&D Progress NSC-8679 - Drug Profile Product Description Mechanism Of Action R&D Progress PTG-300 - Drug Profile Product Description Mechanism Of Action R&D Progress SLN-124 - Drug Profile Product Description Mechanism Of Action R&D Progress VIT-2763 - Drug Profile Product Description Mechanism Of Action R&D Progress Hemochromatosis - Dormant Projects Hemochromatosis - Product Development Milestones Featured News & Press Releases

For more information about this report visit https://www.researchandmarkets.com/research/hsvkxc/hemochromatosis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006236/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 11:01 AM/DISC: 06/05/2018 11:01 AM

http://www.businesswire.com/news/home/20180605006236/en